Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity: a biomarker of blood-cerebrospinal fluid barrier permeability.
The blood-brain barrier, the blood-cerebrospinal fluid barrier (BCB) and other specialized brain barriers are increasingly recognized as a major obstacle to the treatment of most brain disorders. The impairment of these barriers has been implicated in neuropathology of several diseases, such as autism, ischemia, multiple sclerosis and Alzheimer disease. This dual function of the blood-neural barriers points out the importance and need for the development of techniques that can evaluate the nature and level of their integrity. Here we report the discovery of CSF secretory Ca(2+)-dependent phospholipase A2 (sPLA2) activity as a measure of BCB permeability. Lumbar CSF from BCB impaired (n=26), multiple sclerosis (n=18) and healthy control (n=32) cases was analyzed using both a newly developed continuous fluorescence assay for CSF sPLA2 activity and CSF/Serum albumin ratio (Q(Alb)), the most common and established method to evaluate BCB permeability. While both measurements showed no significant differences between multiple sclerosis and age-matched normal healthy cases, they were highly correlated. Though the CSF sPLA2 activity and Q(Alb) had over 95% agreement, the former was found to be more sensitive than the latter in measuring low levels of BCB impairment.
Chalbot
Sonia
S
New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York 10314-6399, USA.
Zetterberg
Henrik
H
Blennow
Kaj
K
Fladby
Tormod
T
Grundke-Iqbal
Inge
I
Iqbal
Khalid
K
D000328:Adult; D000418:Albumins / Q000134:cerebrospinal fluid / Q000378:metabolism; D015415:Biomarkers / Q000134:cerebrospinal fluid; D001808:Blood Vessels / Q000502:physiology*; D049428:Blood-Nerve Barrier; D002199:Capillary Permeability / Q000502:physiology*; D016022:Case-Control Studies; D002555:Cerebrospinal Fluid / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000134:cerebrospinal fluid; D054497:Phospholipases A2, Secretory / Q000134:cerebrospinal fluid*; D012189:Retrospective Studies
D000418:Albumins; D015415:Biomarkers; D054497:Phospholipases A2, Secretory
Lancet. 1986 Feb 8;1(8476):307-10
2868172
J Magn Reson Imaging. 2008 Aug;28(2):284-6
18666152
Cell Mol Neurobiol. 2000 Apr;20(2):131-47
10696506
Curr Pharm Des. 2005;11(10):1301-12
15853686
Neurology. 2004 Nov 23;63(10):1966-7
15557527
Annu Rev Immunol. 2005;23:683-747
15771584
Neuroscientist. 2006 Jun;12(3):245-60
16684969
Int J Mol Med. 2005 Sep;16(3):449-53
16077954
Alzheimer Dis Assoc Disord. 1997 Jun;11(2):78-87
9194954
BMB Rep. 2008 May 31;41(5):345-52
18510863
Scand J Clin Lab Invest. 1977 Sep;37(5):385-90
337459
J Neuroinflammation. 2006 Oct 07;3:28
17026770
J Neuroimmunol. 1998 Feb;82(1):5-12
9526840
J Allergy Clin Immunol. 2005 Nov;116(5):1000-6
16275367
Pharm Res. 2005 Jul;22(7):1011-37
16028003
J Exp Med. 2005 Sep 19;202(6):841-51
16172261
J Neuroimmunol. 2003 Apr;137(1-2):210-7
12667665
Brain. 2009 May;132(Pt 5):1221-35
19218359
Clin Chem Lab Med. 2008;46(7):1046-9
18605944
Glia. 2003 Dec;44(3):275-82
14603468
Clin Chem. 2009 Dec;55(12):2171-9
19850632
Eur Neurol. 1993;33(2):129-33
8467819
Neurology. 1990 Feb;40(2):229-35
2300240
Clin Chem. 1974 May;20(5):571-3
4207912
J Neurol. 2000 Aug;247(8):616-22
11041329
J Lipid Res. 2004 Feb;45(2):205-13
14657205
Neuron. 2004 Feb 5;41(3):323-35
14766173
J Neuroinflammation. 2006 Sep 11;3:26
16965627
Neurochem Res. 1995 Nov;20(11):1335-43
8786820
Brain. 1990 Oct;113 ( Pt 5):1477-89
2245307
Restor Neurol Neurosci. 2003;21(3-4):75-7
14530571
Radiology. 1986 Dec;161(3):721-5
3786722